Article Text

Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature
  1. Sabrina Bajwah1,2,
  2. Joy R Ross1,3,
  3. Janet L Peacock4,
  4. Irene J Higginson2,
  5. Athol U Wells3,5,
  6. Amit Suresh Patel6,
  7. Jonathan Koffman2,
  8. Julia Riley1,3
  1. 1Department of Palliative Medicine, Royal Marsden and Royal Brompton NHS Foundation Trusts, London, UK
  2. 2Department of Palliative Care, Policy and Rehabilitation, King's College London, Cicely Saunders Institute, London, UK
  3. 3National Heart and Lung Institute, Imperial College, London, UK
  4. 4Division of Health and Social Care Research, King's College London, London, UK
  5. 5Department of Respiratory Medicine, Royal Brompton NHS Foundation Trust, London, UK
  6. 6Department of Respiratory Medicine, King's College Hospital, London, UK
  1. Correspondence to Dr Sabrina Bajwah, Department of Palliative Medicine, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK; sabrina.bajwah{at}


Background Patients with fibrotic interstitial lung disease have symptom control and quality of life (QoL) needs. This review aims to evaluate the evidence for the use of interventions in improving dyspnoea, other symptoms and QoL.

Methods Eleven databases, relevant websites and key journals were hand-searched. Studies were assessed and data extracted independently by two researchers using standardised proformas. Meta-analyses were performed where possible with 95% CI.

Results 34 papers with 19 interventions in 3635 patients were included. Meta-analyses showed no significant effect of interferon γ-1b or sildenafil on 6-minute walking distance (6MWD) or dyspnoea. Pulmonary rehabilitation and pirfenidone had a positive effect on 6MWD (mean difference (95% CI) 27.4 (4.1 to 50.7)) and 24.0 (4.3 to 43.7), respectively), and pulmonary rehabilitation had a mixed effect on dyspnoea. Both pulmonary rehabilitation and sildenafil showed a trend towards significance in improving QoL. There was weak evidence for the improvement of 6MWD using oxygen; dyspnoea using prednisolone, diamorphine, D-pencillamine and colchicine; cough using interferon α and thalidomide; anxiety using diamorphine; fatigue using pulmonary rehabilitation; and QoL using thalidomide and doxycycline. A wide range of outcome scales was used and there were no studies with economic evaluation.

Conclusions There is strong evidence for the use of pulmonary rehabilitation and pirfenidone to improve 6MWD and moderate evidence for the use of sildenafil and pulmonary rehabilitation to improve QoL. Future recommendations for research would include careful consideration of the dichotomy of radical and palliative treatments when deciding on how symptom and QoL outcome measures are used and data presented.

  • Interstitial Fibrosis
  • Palliative Care
  • Pulmonary Rehabilitation
View Full Text

Statistics from

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.